Wednesday, July 8, 2026

Patent intelligence · US

US 11534474

Oral compositions for bladder regulation and uses thereof

granted A61KA61K36/076A61K36/21A61K36/40
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 16
Applicant portfolio 4
Patent details — US 11534474
Jurisdiction
US
Status
granted
Grant date
Dec 27, 2022
Expiration
Dec 22, 2042
Claims
26
CPC classes
A61K, A61K36/076, A61K36/21, A61K36/40
View on Google Patents ↗

Quick answer

US 11534474 (Oral compositions for bladder regulation and uses thereof) is held by AYTU BIOPHARMA, INC.. Status: granted. Granted Dec 27, 2022. Expires Dec 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
26
CPC classes
A61K, A61K36/076, A61K36/21, A61K36/40, A61K36/54, A61K36/64

More from AYTU BIOPHARMA, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 10184931

    Methods and systems for measuring and using the oxidation-reduction potential of a biological sample

    Aytu BioScience, Inc. · Expires Jan 17, 2039

    granted
  2. US 9410913

    Methods and systems for measuring and using the oxidation-reduction potential of a biological sample

    Aytu BioScience, Inc. · Expires Aug 4, 2036

    granted
  3. US 9360446

    Methods and systems for measuring and using the oxidation-reduction potential of a biological sample

    Aytu BioScience, Inc. · Expires Jun 2, 2036

    granted

Frequently asked questions

What is US patent 11534474?

US 11534474 (Oral compositions for bladder regulation and uses thereof) is held by AYTU BIOPHARMA, INC.. Status: granted. Granted Dec 27, 2022. Expires Dec 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11534474?

AYTU BIOPHARMA, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.

When does US 11534474 expire?

Our index shows an expiration date of Dec 22, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.